Global LKS Treatment Market, By Type, By Treatment, By Diagnosis, By End User, By Region, Competition Forecast and Opportunities, 2017-2027 – Yahoo…

ReportLinker

Global LKS Treatment Market, By Type (Focal Motor Seizures, Tonic Seizures, Atonic Seizures), By Treatment (Anticonvulsant Drugs, Corticosteroids, Intravenous Immunoglobulins, Surgery, Speech Therapy, Others), By Diagnosis (Electroencephalogram (EEG), MRI, Audiometry, Genetic Testing, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, Competition Forecast and Opportunities, 2017-2027

New York, April 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global LKS Treatment Market, By Type, By Treatment, By Diagnosis, By End User, By Region, Competition Forecast and Opportunities, 2017-2027" - https://www.reportlinker.com/p06267903/?utm_source=GNW

The global LKS treatment market is projected to register growth at a significate rate during the forecast period.The market growth can be attributed to the rising incidences of genetic disorders like LKS syndrome and the increasing demand for effective treatments for speech impairments.

Landau-Kleffner syndrome (LKS) is a rare neurogenerative disease often affecting children within the age group of 4 to 7 years.The disease caused by gene mutations can affect the speaking and cognitive abilities of the individual.

LKS is more prevalent among males than females.Some of the symptoms of LKS include speech impairment, verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and overt seizures.

Rapidly emerging treatment options for managing and treating the symptoms of LKS are supporting the growth of the global LKS treatment market. Surging demand for effective treatment and the growing number of treatment options are further accelerating the growth of the global LKS treatment market. Rising health awareness among the global population and early diagnosis and effective treatment are also contributing to the growth of the global LKS treatment market. The emergence of diseases similar to LKS is creating a demand for pharmaceutical products and therapeutic treatments, which is anticipated to boost the global LKS treatment market growth. Advancing healthcare infrastructure and the development of better pharmaceutical drugs are also supporting the growth of the global LKS treatment market growth. The global LKS treatment market is segmented on the basis of type, treatment, diagnosis, end user, regional distribution, and competitional landscape.Based on treatment, the market is sub-divided into anticonvulsant drugs, corticosteroids, intravenous immunoglobulins, surgery, speech therapy, and others.

Anticonvulsant drugs are anticipated to register the highest growth in the global LKS treatment market during the forecast period due to rapidly increasing advancements in pharmaceutical products and rising incidences of seizures and convulsions among patients suffering from LKS. Major players operating in the global LKS treatment market are Johnson & Johnson, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Abbott Laboratories, Inc., Cipla, Inc., Glenmark Pharmaceuticals Limited, Mankind Pharma Limited, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, etc.

Years considered for this report:

Historical Years: 2017-2020 Base Year: 2021 Estimated Year: 2022E Forecast Period: 2023F2027F

Objective of the Study:

To analyze the historical growth in the market size of global LKS treatment market from 2017 to 2021. To estimate and forecast the market size of global LKS treatment market from 2022 to 2027 and growth rate until 2027. To classify and forecast global LKS treatment market based on type, treatment, diagnosis, end user, region, and competitive landscape. To identify dominant region or segment in the global LKS treatment market. To identify drivers and challenges for global LKS treatment market. To examine competitive developments such as expansions, new services, mergers & acquisitions, etc., in global LKS treatment market. To identify and analyze the profile of leading players operating in global LKS treatment market. To identify key sustainable strategies adopted by market players in global LKS treatment market.

Report Scope:

In this report, global LKS treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below: LKS Treatment Market, By Type: o Focal Motor Seizures o Tonic Seizures o Atonic Seizures LKS Treatment Market, By Treatment: o Anticonvulsant Drugs o Corticosteroids o Intravenous Immunoglobulins o Surgery o Speech Therapy o Others LKS Treatment Market, By Diagnosis: o Electroencephalogram (EEG) o MRI o Audiometry o Genetic Testing o Others LKS Treatment Market, By End User: o Hospitals & Clinics o Ambulatory Care Centers o Others LKS Treatment Market, By Region: o North America United States Mexico Canada o Europe France Germany United Kingdom Italy Spain o Asia-Pacific China India Japan South Korea Australia o Middle East & Africa South Africa Saudi Arabia UAE o South America Brazil Argentina Colombia

The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of companies across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, TechSci Research was not able to include the companies, which could not be identified due to the limitations of secondary research. The analyst examined the companies and presence of all major players across the globe. The analyst calculated the market size of global LKS treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these treatments for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

LKS treatment service provider companies/partners End-Users Government bodies such as regulating authorities and policy makers Organizations, industry associations, forums and alliances related to global LKS treatment market The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc. besides allowing them in strategizing investments and capitalizing on market opportunities.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global LKS treatment market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five). Read the full report: https://www.reportlinker.com/p06267903/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See original here:
Global LKS Treatment Market, By Type, By Treatment, By Diagnosis, By End User, By Region, Competition Forecast and Opportunities, 2017-2027 - Yahoo...

Hataali wins US patent for the use of blockchain in advanced medicinal therapy products – Bio-IT World

ATMPS Ltd/Hataali the leader in blockchain-based data sharing platforms for advanced therapies announces it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of blockchain technologies in personalised medicines. The company also has applications pending in both Europe and Asia as it looks to cement its technological advantage in the rapidly growing advanced therapy space globally.

The new patent comes at a key time for the pharma industry with more than ten advanced therapies anticipated to be approved in the next year as pharma companies continue to struggle with how to effectively and safely scale-up production. The challenge is that without a blockchain based solution like Hataali, they dont have a suitable platform to communicate and coordinate their activities to ensure effective commercialisation. Hataalis incorruptible data solution to track therapies through a complex supply chain ensures patient safety as well as more efficient regulatory compliance meaning a full digital solution with many in active trials still relying upon unsuitable paper-based tracking.

Its a big moment for Hataali as it means we have the exclusive use of blockchain the only technology so far proven to overcome the challenges of effective scale-up in advanced therapy medicinal products in the United States. Up until now, you have several companies trying to shoehorn in unsuitable old point to point technologies as a solution for cell and gene therapy tracking. They have simply not worked and we expect to take a dominant position over the next few years as it becomes apparent we have the only solution for a cost effective mass roll out of these therapies, commented Raja Sharif, CEO at Hataali.

The patent is also seen as a much wider pivotal moment for pharma as it accelerates adoption of blockchain technologies, which are already reaching wider maturity in the other industries like Fintech. Beyond solving the significant problem of cell and gene therapy tracking, blockchain will also empower the industry with potentially more streamlined applications and even payments whereby smart contracts offer the ability for providers to automate payments once clinical outcomes have been reached.

Sharif added: Hataali, being a single portal for multiple therapies, from multiple pharma companies for multiple sites will revolutionise the administration of cell and gene therapies. Our patent is one huge step along in helping the industry relieve the well documented congestion in therapy rollout and scale-up, as more pharma companies win approvals. The single portal approach makes it far easier for clinics to order and schedule these treatments. Without a robust technology to track products from vein to vein, we simply wont be able to get these lifesaving therapies out to the patients that need them quickly enough. Hataali solves this problem and will be a big enabler of the mass adoption of these next generation therapies.

ATMPS Ltd was also bestowed the Bionow Technical Service Award at the 20th Bionow Annual Awards Dinner in Manchester last week. The award recognised the Hataali blockchain-based platform for ATMP supply chains for its ability to allow its partners in personalised medicine to ensure that data necessary for the production of treatments can be shared between parties in a secure, confidential and regulatory compliant manner.

Read the original:
Hataali wins US patent for the use of blockchain in advanced medicinal therapy products - Bio-IT World

Five things for pharma marketers to know: Thursday, April 14, 2022 – Medical Marketing and Media

Uninsured Americans may have to pay for COVID-19 testing at certain labs due to federal funding running dry. The Senates $10 billion bipartisan pandemic aid bill doesnt include the Biden administrations request for $1.5 billion to cover testing and treatment for people without health insurance. (CNBC Weekly)

Bluebird Bios gene therapy Zynteglo, which has a proposed price of $2.1 million per treatment course, could still be cost-effective, according to the Institute for Clinical and Economic Review. The therapy is set to be reviewed by the Food and Drug Administration in June. (Endpoints News)

The U.S. Department of Justice is investigating Bausch Health over the marketing of skin condition medications. The inquiry is seeking information about the promotion of plaque psoriasis drugs Bryhali, Siliq and Duobrii for uses not approved by regulators. (STAT)

Halozyme Therapeutics announced that it will buy Antares Pharma for nearly $1 billion. The acquisition will allow Halozyme to expand into drug delivery and specialty medicines. (The Wall Street Journal)

STD cases soared during the pandemic, with gonorrhea and syphilis cases reaching record highs during the first year of COVID-19, according to new data from the Centers for Disease Control and Prevention). Despite high case counts, however, fewer federal funds are being directed to sexual health clinics. (Politico)

View post:
Five things for pharma marketers to know: Thursday, April 14, 2022 - Medical Marketing and Media

Beware of trans affirmation therapy | Julie Bindel – The Critic

Beware of trans affirmation therapy is the latest article in Julie Bindels online column for The Critic, The feminist fix, which explores feminisms answer to todays challenges. The previous article, on Will Smiths sexist excuses for violence, can be read here.

This week the government has banned conversion therapy for gays but, in a major kerfuffle, not for trans people. I wasnt surprised. As the EHRC rightly points out, the Government consultation document on the topic contained no clear definition of what will amount to conversion therapy. Neither was it clear about the meaning of transgender; a term which has no clear legal meaning, is potentially wider than the concept of gender reassignment in current UK law, and is understood by different people in different ways. So why all the confusion? What does this all mean for gay and dysphoric youth? And how does it relate to my own experience of conversion therapy?

In 2014, during research for a book on lesbian and gay culture I decided to challenge some of the mythology around what conversion therapy actually is and is not. I was sick of some conservative-minded gay men who would only speak out against conversion therapy because they believed that there is something such as a gay gene, and therefore sexuality is hard-wired in the womb. Their argument was, in a nutshell, that lesbians and gay men should be afforded tolerance on the basis that we cant help it.

These gay men argued that the born this way strategy would overcome prejudice and achieve equality. I disagree. Firstly, I have long been sceptical of the notion that sexual orientation is in any way predetermined. Even if the gay gene were found once and for all, what difference would it make?

Whether you are black, disabled, Jewish or belong to many oppressed minority groups may be determined at least in part by genes, but this has not prevented prejudice and discrimination towards these groups. To my mind, it is politically immature to argue for our rights on the grounds that we have no control over what and who we are.

I voluntarily undertook a gruelling week of intensive therapy

Although many lesbians experience our sexual desires as hard-wired from an early age, many others are only able to come out later in life having been railroaded into what feminists refer to as compulsory heterosexuality. This may include a variety of societal expectations, marriage to men, social opprobrium directed at lesbians and lesbian relationships, religion, and distaste for the depiction of lesbian relationships as they are portrayed in culture (e.g., porn). Many more women would be lesbians, these feminists argue, if they were freer from these constraints of patriarchy.

We are all subject to those forces, to different degrees and in different ways. Many lesbians and gay men have undergone more extreme and traumatic pressure, including conversion therapy. This therapy seeks to convert them to exclusively heterosexual practices (if not desires) and may involve extreme and abusive techniques.

Whilst researching my book, I went undercover, posing as a lesbian who wanted to be straight, in order to experience a gruelling week of intensive therapy. I was told, for eight hours each day, that I was broken, badly raised, sexually abused in childhood, mentally unwell, running from God. Even though I was in role, like an actor on set, I would return to my hotel every evening experiencing low moods, panic attacks and self-doubt.

I had been out as a lesbian for almost 40 years when I underwent this conversion therapy, and I was by no means forced or even persuaded to undergo it, but I still didnt escape the horrors, or the aftereffects. The effects of this type of therapy on a young person are often utterly devastating.

Trans Rights Activists in this debate are trying to compare the type of therapy I underwent to offering exploratory talking therapies to nonconforming or gender dysphoric young people. The only therapeutic approach acceptable to these extremists is the affirmation model. What does this look like for nonconforming and dysphoric youth?

As a 15-year-old I felt really grim about being a girl and a lesbian. Because I was attracted to girls, and rejected feminine frippery, I was constantly asked if I was a boy. Young women throughout the ages have had similar experiences, but nowadays if they go to a gender clinic, they may end up in affirmation therapy. They will be prescribed puberty blockers, followed by testosterone, double mastectomy, hysterectomy and lifelong medical treatment.

Rather than asking are you okay, this new model affirms teenagers in their chosen gender identities. Rather than asking whether teenagers are unhappy because they are being bullied for their sexuality, they are given unnecessary hormones. If they dont get these fast enough from one therapist, there is evidence that they go shopping for another one.

Growing up, girls are shamed for their periods; they watch their male peers overtake them in size and strength; they become subject to the male gaze; they are catcalled, objectified, sexually abused; they often feel powerless and sometimes out of control. For many of these girls, a male identification is a shield against all of this, maybe the first time theyve made a stand and tried to take up some space.

Being gay requires no hormones, surgeries or deception

Responsible, empathic therapy has to deal with this, and help these young women to understand why they feel how they do, before setting them on the road to a lifetime of unnecessary medical treatments. It is precisely this type of therapy that trans activists wish to ban.

They want to ban the type of support that would have helped me: a confused, self-hating teenager, who would have grabbed the opportunity to transition with both hands. And yet, here I am, an out and proud lesbian of more than 40 years.

That said, I really couldve done with some therapy when I was struggling with the feelings I had developed for a girl in my class a friendly, skilled ear, to listen to my distress and tell me I was perfectly fine as I was. A good dose of feminism would have helped me to understand why anti-lesbian prejudice exists, and how it contributed to my distress. The kids today are no different. But instead of being given the tools to fight their oppression, they are presenting at gender clinics and being put on hormones.

It is known that the majority of children who develop gender dysphoria go on to be lesbian or gay later in life, and continue to live as their biological sex, if only they can avoid being affirmed as trans and going down the medical pathway.

Being gay requires no hormones or surgeries, and no deception. On the other hand, instant affirmation of a trans identity for young gender nonconforming people is nothing more and nothing less than selling the medicalised lie to lesbian and gay young people: that they can somehow become straight. Affirmation therapy on the one hand, and gay conversion therapy on the other, are human rights violations and unacceptable on every level.

The feminist fix? Rather than telling confused children that the reason for their distress is that they are actually the opposite sex, give them a listening ear, and a good understanding of how women and girls are treated, and a feminist community, and some really good books. Turns out that the feminist fix is feminism.

Julie Bindels latest book,Feminism for Women: The Real Route to Liberation, was published in September 2021.

More:
Beware of trans affirmation therapy | Julie Bindel - The Critic